{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:51Z","timestamp":1793830911327,"version":"4.6.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CASES:<\/jats:title>\n            <jats:p>Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000005154","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T21:10:50Z","timestamp":1680815450000},"page":"1019-1023","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer"],"prefix":"10.1097","volume":"141","author":[{"given":"Aliyah B.","family":"Conley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith F.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Frumovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J Clin"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous ovarian carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J Clin Oncol"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2407-8-252","article-title":"Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study","volume":"8","author":"Pignata","year":"2008","journal-title":"BMC Cancer"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2010.02.010","article-title":"Unmasking the complexities of mucinous ovarian carcinoma","volume":"117","author":"Frumovitz","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/AOG.0000000000003579","article-title":"Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma","volume":"134","author":"Kurnit","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1245\/s10434-021-09927-7","article-title":"The landmark series: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) for treatment of gastric cancer metastatic to peritoneum","volume":"28","author":"Dineen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R10-20250430","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"key":"R11-20250430","doi-asserted-by":"crossref","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"key":"R12-20250430","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20250430","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"key":"R15-20250430","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003806","article-title":"Primary mucinous ovarian cancer: options for surgery and chemotherapy","author":"Kurnit","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.sla.0000133183.15705.71","article-title":"Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy","volume":"240","author":"Glehen","year":"2004","journal-title":"Ann Surg"},{"key":"R18-20250430","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R19-20250430","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jamcollsurg.2009.04.019","article-title":"Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology","volume":"209","author":"Omohwo","year":"2009","journal-title":"J Am Coll Surgeons"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J Am Coll Surgeons"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","article-title":"Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy","volume":"6","author":"Sugarbaker","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"R22-20250430","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1245\/s10434-018-6464-z","article-title":"Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE","volume":"25","author":"Mercier","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R24-20250430","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: ovarian cancer, version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: a phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum sensitive-recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int J Cancer"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:48:08Z","timestamp":1746082088000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005154","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"2022-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}